{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T16:33:00Z","timestamp":1772555580005,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2009,9,2]],"date-time":"2009-09-02T00:00:00Z","timestamp":1251849600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2009,9,2]],"date-time":"2009-09-02T00:00:00Z","timestamp":1251849600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>Evidence suggests that citrullinated fibrin(ogen) may be a potential <jats:italic>in vivo<\/jats:italic> target of anticitrullinated protein\/peptide antibodies (ACPA) in rheumatoid arthritis (RA). We compared the diagnostic yield of three enzyme-linked immunosorbent assay (ELISA) tests by using chimeric fibrin\/filaggrin citrullinated synthetic peptides (CFFCP1, CFFCP2, CFFCP3) with a commercial CCP2-based test in RA and analyzed their prognostic values in early RA.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>Samples from 307 blood donors and patients with RA (322), psoriatic arthritis (133), systemic lupus erythematosus (119), and hepatitis C infection (84) were assayed by using CFFCP- and CCP2-based tests. Autoantibodies also were analyzed at baseline and during a 2-year follow-up in 98 early RA patients to determine their prognostic value.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>With cutoffs giving 98% specificity for RA versus blood donors, the sensitivity was 72.1% for CFFCP1, 78.0% for CFFCP2, 71.4% for CFFCP3, and 73.9% for CCP2, with positive predictive values greater than 97% in all cases. CFFCP sensitivity in RA increased to 80.4% without losing specificity when positivity was considered as any positive anti-CFFCP status. Specificity of the three CFFCP tests versus other rheumatic populations was high (&gt; 90%) and similar to those for the CCP2. In early RA, CFFCP1 best identified patients with a poor radiographic outcome. Radiographic progression was faster in the small subgroup of CCP2-negative and CFFCP1-positive patients than in those negative for both autoantibodies. CFFCP antibodies decreased after 1 year, but without any correlation with changes in disease activity.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>CFFCP-based assays are highly sensitive and specific for RA. Early RA patients with anti-CFFCP1 antibodies, including CCP2-negative patients, show greater radiographic progression.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/ar2802","type":"journal-article","created":{"date-parts":[[2009,9,2]],"date-time":"2009-09-02T18:14:32Z","timestamp":1251915272000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Diagnostic and prognostic value of antibodies against chimeric fibrin\/filaggrin citrullinated synthetic peptides in rheumatoid arthritis"],"prefix":"10.1186","volume":"11","author":[{"given":"Raimon","family":"Sanmart\u00ed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduard","family":"Graell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria L","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guadalupe","family":"Ercilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Odette","family":"Vi\u00f1as","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose A","family":"G\u00f3mez-Puerta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Gratac\u00f3s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Balsa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria J","family":"G\u00f3mara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Larrosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan D","family":"Ca\u00f1ete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Haro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,9,2]]},"reference":[{"key":"2639_CR1","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.cair.2003.11.001","volume":"4","author":"ER Vossenaar","year":"2004","unstructured":"Vossenaar ER, van Venrooij WJ: Anti-CCP antibodies, a highly specific marker for (early) rheumatoid arthritis. Clin Applied Immunol Rev. 2004, 4: 239-262. 10.1016\/j.cair.2003.11.001.","journal-title":"Clin Applied Immunol Rev"},{"key":"2639_CR2","doi-asserted-by":"publisher","first-page":"797","DOI":"10.7326\/0003-4819-146-11-200706050-00008","volume":"146","author":"K Nishimura","year":"2007","unstructured":"Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, Saigo K, Morinobu A, Koshiba M, Kuntz KM, Kamae I, Kumagai S: Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. 2007, 146: 797-808.","journal-title":"Ann Intern Med"},{"key":"2639_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.autrev.2006.03.008","volume":"6","author":"WJ van Venrooij","year":"2006","unstructured":"van Venrooij WJ, Zendman AJ, Pruijn GJ: Autoantibodies to citrullinated antigens in (early) rheumatoid arthritis. Autoimmun Rev. 2006, 6: 37-41. 10.1016\/j.autrev.2006.03.008.","journal-title":"Autoimmun Rev"},{"key":"2639_CR4","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/art.10117","volume":"46","author":"H Visser","year":"2002","unstructured":"Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM: How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum. 2002, 46: 357-365. 10.1002\/art.10117.","journal-title":"Arthritis Rheum"},{"key":"2639_CR5","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/art.20044","volume":"50","author":"FA van Gaalen","year":"2004","unstructured":"van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, Toes RE, Huizinga TW: Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum. 2004, 50: 709-715. 10.1002\/art.20044.","journal-title":"Arthritis Rheum"},{"key":"2639_CR6","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1136\/ard.62.2.120","volume":"62","author":"O Meyer","year":"2003","unstructured":"Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois A, Nicaise-Roland P, Sibilia J, Combe B: Anticitrullinated protein\/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis. 2003, 62: 120-126. 10.1136\/ard.62.2.120.","journal-title":"Ann Rheum Dis"},{"key":"2639_CR7","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1136\/ard.2003.014233","volume":"63","author":"K Forslind","year":"2004","unstructured":"Forslind K, Ahlmen M, Eberhardt K, Hafstrom I, Svensson B: Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis. 2004, 63: 1090-1095. 10.1136\/ard.2003.014233.","journal-title":"Ann Rheum Dis"},{"key":"2639_CR8","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1136\/ard.2003.017574","volume":"63","author":"L De Rycke","year":"2004","unstructured":"De Rycke L, Peene I, Hoffman IE, Kruithof E, Union A, Meheus L, Lebeer K, Wyns B, Vincent C, Mielants H, Boullart L, Serre G, Veys EM, De Keyser F: Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis. 2004, 63: 1587-1593. 10.1136\/ard.2003.017574.","journal-title":"Ann Rheum Dis"},{"key":"2639_CR9","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.1002\/art.21385","volume":"52","author":"TW Huizinga","year":"2005","unstructured":"Huizinga TW, Amos CI, Helm-van Mil van der AH, Chen W, van Gaalen FA, Jawaheer D, Schreuder GM, Wener M, Breedveld FC, Ahmad N, Lum RF, de Vries RR, Gregersen PK, Toes RE, Criswell LA: Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum. 2005, 52: 3433-3438. 10.1002\/art.21385.","journal-title":"Arthritis Rheum"},{"key":"2639_CR10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/art.21575","volume":"54","author":"L Klareskog","year":"2006","unstructured":"Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J, Ronnelid J, Harris HE, Ulfgren AK, Rantapaa-Dahlqvist S, Eklund A, Padyukov L, Alfredsson L: A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006, 54: 38-46. 10.1002\/art.21575.","journal-title":"Arthritis Rheum"},{"key":"2639_CR11","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1172\/JCI1316","volume":"101","author":"GA Schellekens","year":"1998","unstructured":"Schellekens GA, de Jong BA, Hoogen van den FH, Putte van de LB, van Venrooij WJ: Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1998, 101: 273-281. 10.1172\/JCI1316.","journal-title":"J Clin Invest"},{"key":"2639_CR12","first-page":"1002","volume":"35","author":"L Innala","year":"2008","unstructured":"Innala L, Kokkonen H, Eriksson C, Jidell E, Berglin E, Dahlqvst SR: Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J Rheumatol. 2008, 35: 1002-1008.","journal-title":"J Rheumatol"},{"key":"2639_CR13","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1136\/ard.2004.029389","volume":"64","author":"MM Nielen","year":"2005","unstructured":"Nielen MM, Horst van der AR, van Schaardenburg D, Horst-Bruinsma van der IE, Stadt van de RJ, Aarden L, Dijkmans BA, Hamann D: Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. Ann Rheum Dis. 2005, 64: 1199-1204. 10.1136\/ard.2004.029389.","journal-title":"Ann Rheum Dis"},{"key":"2639_CR14","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1515\/CCLM.2007.294","volume":"45","author":"J Luis Caro-Oleas","year":"2007","unstructured":"Luis Caro-Oleas J, Fernandez-Suarez A, Reneses Cesteros S, Porrino C, Nunez-Roldan A, Wichmann Schlipf I: Diagnostic usefulness of a third-generation anti-cyclic citrulline antibody test in patients with recent-onset polyarthritis. Clin Chem Lab Med. 2007, 45: 1396-1401. 10.1515\/CCLM.2007.294.","journal-title":"Clin Chem Lab Med"},{"key":"2639_CR15","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1373\/clinchem.2007.087569","volume":"53","author":"N Bizzaro","year":"2007","unstructured":"Bizzaro N, Tonutti E, Tozzoli R, Villalta D: Analytical and diagnostic characteristics of 11 2nd- and 3rd-generation immunoenzymatic methods for the detection of antibodies to citrullinated proteins. Clin Chem. 2007, 53: 1527-1533. 10.1373\/clinchem.2007.087569.","journal-title":"Clin Chem"},{"key":"2639_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/ar2504","volume":"10","author":"WJ van Venrooij","year":"2008","unstructured":"van Venrooij WJ, Pruijn GJ: An important step towards completing the rheumatoid arthritis cycle. Arthritis Res Ther. 2008, 10: 117-10.1186\/ar2504.","journal-title":"Arthritis Res Ther"},{"key":"2639_CR17","doi-asserted-by":"publisher","first-page":"4177","DOI":"10.4049\/jimmunol.166.6.4177","volume":"166","author":"C Masson-Bessiere","year":"2001","unstructured":"Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, Nogueira L, Vincent C, Senshu T, Serre G: The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol. 2001, 166: 4177-4184.","journal-title":"J Immunol"},{"key":"2639_CR18","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1002\/eji.200535790","volume":"36","author":"M Sebbag","year":"2006","unstructured":"Sebbag M, Moinard N, Auger I, Clavel C, Arnaud J, Nogueira L, Roudier J, Serre G: Epitopes of human fibrin recognized by the rheumatoid arthritis-specific autoantibodies to citrullinated proteins. Eur J Immunol. 2006, 36: 2250-2263. 10.1002\/eji.200535790.","journal-title":"Eur J Immunol"},{"key":"2639_CR19","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/j.1747-0285.2006.00438.x","volume":"68","author":"ML Perez","year":"2006","unstructured":"Perez ML, Gomara MJ, Kasi D, Alonso A, Vinas O, Ercilla G, Sanmarti R, Haro I: Synthesis of overlapping fibrin citrullinated peptides and their use for diagnosing rheumatoid arthritis. Chem Biol Drug Des. 2006, 68: 194-200. 10.1111\/j.1747-0285.2006.00438.x.","journal-title":"Chem Biol Drug Des"},{"key":"2639_CR20","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1021\/jm0701932","volume":"50","author":"ML Perez","year":"2007","unstructured":"Perez ML, Gomara MJ, Ercilla G, Sanmarti R, Haro I: Antibodies to citrullinated human fibrinogen synthetic peptides in diagnosing rheumatoid arthritis. J Med Chem. 2007, 50: 3573-3584. 10.1021\/jm0701932.","journal-title":"J Med Chem"},{"key":"2639_CR21","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1093\/rheumatology\/keg284","volume":"42","author":"R Sanmarti","year":"2003","unstructured":"Sanmarti R, Gomez A, Ercilla G, Gratacos J, Larrosa M, Suris X, Vinas O, Salvador G, Munoz-Gomez J, Canete JD: Radiological progression in early rheumatoid arthritis after DMARDS: a one-year follow-up study in a clinical setting. Rheumatology (Oxford). 2003, 42: 1044-1049. 10.1093\/rheumatology\/keg284.","journal-title":"Rheumatology (Oxford)"},{"key":"2639_CR22","first-page":"231","volume":"25","author":"I Vazquez","year":"2007","unstructured":"Vazquez I, Graell E, Gratacos J, Canete JD, Vinas O, Ercilla MG, Gomez A, Hernandez MV, Rodriguez-Cros JR, Larrosa M, Sanmarti R: Prognostic markers of clinical remission in early rheumatoid arthritis after two years of DMARDs in a clinical setting. Clin Exp Rheumatol. 2007, 25: 231-238.","journal-title":"Clin Exp Rheumatol"},{"key":"2639_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"ML Prevoo","year":"1995","unstructured":"Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, Putte van de LB, van Riel PL: Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995, 38: 44-48. 10.1002\/art.1780380107.","journal-title":"Arthritis Rheum"},{"key":"2639_CR24","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1002\/art.1780261107","volume":"26","author":"T Pincus","year":"1983","unstructured":"Pincus T, Summey JA, Soraci SA, Wallston KA, Hummon NP: Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum. 1983, 26: 1346-1353. 10.1002\/art.1780261107.","journal-title":"Arthritis Rheum"},{"key":"2639_CR25","first-page":"264","volume":"27","author":"JR Kirwan","year":"2000","unstructured":"Kirwan JR: Using the Larsen index to assess radiographic progression in rheumatoid arthritis. J Rheumatol. 2000, 27: 264-268.","journal-title":"J Rheumatol"},{"key":"2639_CR26","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1136\/ard.2003.011767","volume":"62","author":"O Sanchez-Pernaute","year":"2003","unstructured":"Sanchez-Pernaute O, Largo R, Calvo E, Alvarez-Soria MA, Egido J, Herrero-Beaumont G: A fibrin based model for rheumatoid synovitis. Ann Rheum Dis. 2003, 62: 1135-1138. 10.1136\/ard.2003.011767.","journal-title":"Ann Rheum Dis"},{"key":"2639_CR27","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/jb\/mvn079","volume":"144","author":"M Nakayama-Hamada","year":"2008","unstructured":"Nakayama-Hamada M, Suzuki A, Furukawa H, Yamada R, Yamamoto K: Citrullinated fibrinogen inhibits thrombin-catalysed fibrin polymerization. J Biochem. 2008, 144: 393-398. 10.1093\/jb\/mvn079.","journal-title":"J Biochem"},{"key":"2639_CR28","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1136\/ard.2005.044743","volume":"65","author":"Y Takizawa","year":"2006","unstructured":"Takizawa Y, Suzuki A, Sawada T, Ohsaka M, Inoue T, Yamada R, Yamamoto K: Citrullinated fibrinogen detected as a soluble citrullinated autoantigen in rheumatoid arthritis synovial fluids. Ann Rheum Dis. 2006, 65: 1013-1020. 10.1136\/ard.2005.044743.","journal-title":"Ann Rheum Dis"},{"key":"2639_CR29","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1084\/jem.20072051","volume":"205","author":"JA Hill","year":"2008","unstructured":"Hill JA, Bell DA, Brintnell W, Yue D, Wehrli B, Jevnikar AM, Lee DM, Hueber W, Robinson WH, Cairns E: Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice. J Exp Med. 2008, 205: 967-979. 10.1084\/jem.20072051.","journal-title":"J Exp Med"},{"key":"2639_CR30","doi-asserted-by":"publisher","first-page":"R94","DOI":"10.1186\/ar2478","volume":"10","author":"X Zhao","year":"2008","unstructured":"Zhao X, Okeke NL, Sharpe O, Batliwalla FM, Lee AT, Ho PP, Tomooka BH, Gregersen PK, Robinson WH: Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis. Arthritis Res Ther. 2008, 10: R94-10.1186\/ar2478.","journal-title":"Arthritis Res Ther"},{"key":"2639_CR31","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/art.23284","volume":"58","author":"C Clavel","year":"2008","unstructured":"Clavel C, Nogueira L, Laurent L, Iobagiu C, Vincent C, Sebbag M, Serre G: Induction of macrophage secretion of tumor necrosis factor alpha through Fcgamma receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen. Arthritis Rheum. 2008, 58: 678-688. 10.1002\/art.23284.","journal-title":"Arthritis Rheum"},{"key":"2639_CR32","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1093\/rheumatology\/kei203","volume":"45","author":"MA Quinn","year":"2006","unstructured":"Quinn MA, Gough AK, Green MJ, Devlin J, Hensor EM, Greenstein A, Fraser A, Emery P: Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology (Oxford). 2006, 45: 478-480. 10.1093\/rheumatology\/kei203.","journal-title":"Rheumatology (Oxford)"},{"key":"2639_CR33","first-page":"77","volume":"35","author":"MT Chan","year":"2008","unstructured":"Chan MT, Owen P, Dunphy J, Cox B, Carmichael C, Korendowych E, McHugh NJ: Associations of erosive arthritis with anti-cyclic citrullinated peptide antibodies and MHC class II alleles in systemic lupus erythematosus. J Rheumatol. 2008, 35: 77-83.","journal-title":"J Rheumatol"},{"key":"2639_CR34","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1177\/0961203307087613","volume":"17","author":"GN Damian-Abrego","year":"2008","unstructured":"Damian-Abrego GN, Cabiedes J, Cabral AR: Anti-citrullinated peptide antibodies in lupus patients with or without deforming arthropathy. Lupus. 2008, 17: 300-304. 10.1177\/0961203307087613.","journal-title":"Lupus"},{"key":"2639_CR35","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3","volume":"43","author":"GA Schellekens","year":"2000","unstructured":"Schellekens GA, Visser H, de Jong BA, Hoogen van den FH, Hazes JM, Breedveld FC, van Venrooij WJ: The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 2000, 43: 155-163. 10.1002\/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3.","journal-title":"Arthritis Rheum"},{"key":"2639_CR36","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1136\/ard.2004.035089","volume":"64","author":"FA van Gaalen","year":"2005","unstructured":"van Gaalen FA, Visser H, Huizinga TW: A comparison of the diagnostic accuracy and prognostic value of the first and second anti-cyclic citrullinated peptides (CCP1 and CCP2) autoantibody tests for rheumatoid arthritis. Ann Rheum Dis. 2005, 64: 1510-1512. 10.1136\/ard.2004.035089.","journal-title":"Ann Rheum Dis"},{"key":"2639_CR37","doi-asserted-by":"publisher","first-page":"R122","DOI":"10.1186\/ar2011","volume":"8","author":"B Vander Cruyssen","year":"2006","unstructured":"Cruyssen Vander B, Cantaert T, Nogueira L, Clavel C, De Rycke L, Dendoven A, Sebag M, Deforce D, Vincent C, Elewaut D, Serre G, De Keyser F: Diagnostic value of anti-human citrullinated fibrinogen ELISA and comparison with four other anti-citrullinated protein assays. Arthritis Res Ther. 2006, 8: R122-10.1186\/ar2011.","journal-title":"Arthritis Res Ther"},{"key":"2639_CR38","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1136\/ard.2007.071654","volume":"67","author":"B Vander Cruyssen","year":"2008","unstructured":"Cruyssen Vander B, Nogueira L, Van Praet J, Deforce D, Elewaut D, Serre G, De Keyser F: Do all anti-citrullinated protein\/peptide antibody tests measure the same? Evaluation of discrepancy between anti-citrullinated protein\/peptide antibody tests in patients with and without rheumatoid arthritis. Ann Rheum Dis. 2008, 67: 542-546. 10.1136\/ard.2007.071654.","journal-title":"Ann Rheum Dis"},{"key":"2639_CR39","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1007\/s10067-007-0544-y","volume":"26","author":"Y Zhao","year":"2007","unstructured":"Zhao Y, Tian X, Li Z: Prevalence and clinical significance of antibodies to citrullinated fibrinogen (ACF) in Chinese patients with rheumatoid arthritis. Clin Rheumatol. 2007, 26: 1505-1512. 10.1007\/s10067-007-0544-y.","journal-title":"Clin Rheumatol"},{"key":"2639_CR40","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/art.23188","volume":"58","author":"L Mathsson","year":"2008","unstructured":"Mathsson L, Mullazehi M, Wick MC, Sjoberg O, van Vollenhoven R, Klareskog L, Ronnelid J: Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum. 2008, 58: 36-45. 10.1002\/art.23188.","journal-title":"Arthritis Rheum"},{"key":"2639_CR41","doi-asserted-by":"publisher","first-page":"R949","DOI":"10.1186\/ar1767","volume":"7","author":"AH van der Helm-van Mil","year":"2005","unstructured":"Helm-van Mil van der AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW: Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther. 2005, 7: R949-R958. 10.1186\/ar1767.","journal-title":"Arthritis Res Ther"},{"key":"2639_CR42","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1136\/ard.2004.033571","volume":"64","author":"J Ronnelid","year":"2005","unstructured":"Ronnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L, van Vollenhoven RF: Longitudinal analysis of citrullinated protein\/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis. 2005, 64: 1744-1749. 10.1136\/ard.2004.033571.","journal-title":"Ann Rheum Dis"},{"key":"2639_CR43","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1002\/art.20659","volume":"50","author":"TR Mikuls","year":"2004","unstructured":"Mikuls TR, O'Dell JR, Stoner JA, Parrish LA, Arend WP, Norris JM, Holers VM: Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum. 2004, 50: 3776-3782. 10.1002\/art.20659.","journal-title":"Arthritis Rheum"},{"key":"2639_CR44","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1196\/annals.1313.031","volume":"1050","author":"A Greiner","year":"2005","unstructured":"Greiner A, Plischke H, Kellner H, Gruber R: Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis. Ann N Y Acad Sci. 2005, 1050: 295-303. 10.1196\/annals.1313.031.","journal-title":"Ann N Y Acad Sci"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar2802.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/ar2802\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar2802.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T11:18:02Z","timestamp":1728386282000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/ar2802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,2]]},"references-count":44,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2009,10]]}},"alternative-id":["2639"],"URL":"https:\/\/doi.org\/10.1186\/ar2802","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,2]]},"assertion":[{"value":"29 April 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2009","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2009","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2009","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R135"}}